

# Strength Conversion in Drug Listing

**Leyla Rahjou-Esfandiary, Pharm. D.**  
Drug Registration and Listing Branch  
Office of Compliance  
CDER | US FDA

CDER Direct Workshop – September 28, 2023

# Learning Objectives

- Describe strength conversion in drug listing
- Provide dosage form examples of strength conversion in listing SPLs
- List potential consequences of incorrect strength conversion in listing SPLs

# Electronic Format



- Registrations and listings (including the submission of updated information) shall be submitted to the Secretary **by electronic means.**
- All information submitted under [part 207] must be transmitted to FDA in **electronic format** by using our electronic drug registration and listing system, **in a form that we can process, review, and archive.**

# Standardization

- Dosage form
- Route of administration
- Strength
- Unit of measure
- Active ingredient and moiety
- Labeling sections

# Strength Conversion

- Required for standardization and compatibility
- Strength cannot be expressed in percentage in an SPL format
  - Must be converted
  - Numerator and denominator

# Strength Fields

- Numerator (strength)
  - Weight or volume of the active ingredient
- Numerator unit
  - Weight or volume unit of measure
- Denominator strength
  - Weight or volume of drug base, or time
- Denominator unit
  - Weight, volume or time unit of measure, or each

# Strength in CDER Direct



SAVE INGREDIENT DELETE INGREDIENT << RETURN

**Note:** The denominator strength and UOM for all ingredients within a product should be the same. Should you need to change the values, all the ingredients added thus far should be deleted and added with the new values.

### INGREDIENT DETAILS

Denominator Strength:	<input type="text" value="1"/>	Unit of Measure:	<input type="text" value="1"/>
Type:	<input type="text" value="Active Ingredient, Ingredient is Basis of Strength"/>		
Ingredient UNII - Name:	<input type="text" value="(362O9ITL9D) ACETAMINOPHEN"/>		
Strength:	<input type="text" value="500"/>	Unit Of Measure:	<input type="text" value="mg"/>
<input type="checkbox"/> Moiety Same as Ingredient			
Active Moiety:	<input type="text" value="(362O9ITL9D) ACETAMINOPHEN"/>		

ADD ACTIVE MOIETY

# Converting a Percentage in SPL



- Mainly depends on the listed drug's dosage form:
  - As w/w - mass (grams) of solute in mass (100 g) of solution, like topical creams and ointments
  - As w/v - mass (grams) of solute in a volume (100 mL) of solution, like oral liquids
  - As v/v - volume (milliliters) of solute in a volume (100 mL) of solution, like alcohol
  - As w/time - mass (grams) of active ingredient released over time, like transdermal and vaginal systems

# Examples



Dosage Form	Numerator Unit	Denominator Unit
Oral Solid (e.g., tablet, capsule, oral film)	Weight	Each
Oral Liquid	Weight	Volume
Topical cream or ointment	Weight	Weight
Transdermal systems	Weight	Time
Swab, Cloth, Sponge (Alcohol)	Volume	Volume

# Injectable Drugs

Product and strength	SPL Numerator Value	SPL Numerator Unit	SPL Denominator Value	SPL Denominator Unit
Drug A for Injection 100 mg/vial	100	mg	1	Each
Drug B Injection 100 mg/20 mL (5 mg/mL)	100	mg	20	mL

# Incorrect Conversion is a Data Deficiency



- Automated validation errors
- No errors generated
  - FDA deficiency letter
  - Compliance case
  - If corrected:
    - Manual override
  - If not corrected:
    - Data inactivation, untitled letter, warning letter

# Challenge Question #1

Which statement is correct?

- A. SPL automated validations detect any strength conversion error
- B. Strength in SPL should always match strength in labeling
- C. Strength in SPL should always align with strength in labeling
- D. As long as the listing SPL is submitted and accepted by FDA, the strength calculation is done correctly

## Challenge Question #2

Which dosage form(s) can be expressed in **weight per volume** in a listing SPL:

- A. Topical gels
- B. Medical gas
- C. Inhalation powder (e.g., dry powder inhaler)
- D. Ophthalmic solution, suspension

# Resources



- [Strength Conversion in Drug Listing | FDA](#)
- [Dosage Forms | FDA](#)
- [https://www.uspnf.com/sites/default/files/usp\\_pdf/EN/USPNF/revisions/gc-7-ira-20200731.pdf](https://www.uspnf.com/sites/default/files/usp_pdf/EN/USPNF/revisions/gc-7-ira-20200731.pdf)
- [List of Error-Prone Abbreviations | Institute For Safe Medication Practices \(ismp.org\)](#)



**U.S. FOOD & DRUG**  
ADMINISTRATION

# Questions?

**Leyla Rahjou-Esfandiary, Pharm. D.**

[Leyla.Rahjou-Esfandiary@fda.hhs.gov](mailto:Leyla.Rahjou-Esfandiary@fda.hhs.gov)

[eDRLS@fda.hhs.gov](mailto:eDRLS@fda.hhs.gov)